Economic evaluation of Erdafitinib as a second-line treatment for advanced metastatic urothelial carcinoma: real-world data from the USA and prospective analysis from China
Authors:
- 10 May 2025
- journal article
- Published by Taylor & Francis in Future Oncology
- Vol. 21 (15) , 1919-1927
Abstract
Metastatic urothelial carcinoma (mUC) is challenging to treat, with 37% of patients failing first-line therapy. Effective second-line treatments, like Erdafitinib, are crucial. This study evaluates the cost-effectiveness of Erdafitinib as a second-line treatment for mUC from US and Chinese payer perspectives. A Markov model was developed to project costs, life years, and quality-adjusted life years (QALYs) over lifetime. Data were collected from December 2023 to December 2024 for up-to-date estimates and were obtained from literature, health databases, and clinical trials.. The model was run to project long-term outcomes for both the United States and China. In the United States, Erdafitinib provides an additional 0.467 QALYs at a cost of $238,294.2 per QALY, which exceeds the $150,000 per QALY willingness-to-pay threshold. For China, when the cost of Erdafitinib is below $6.9 or $14 per milligram, there is a 90% probability that its incremental cost-effectiveness ratio will be below $38,223 or $84,966 per QALY, respectively. From the perspective of U.S. payers, Erdafitinib as a second-line treatment for mUC is not cost-effective. From the perspective of China, the cost-effectiveness of Erdafitinib is highly sensitive to its price, which could provide a reference for healthcare reimbursement negotiations.Keywords
Funding Information
- National Natural Science Foundation of China (71874209)
- the research project of the Health Commission of Hunan province (202113050283)
- the Fundamental Research Funds for the Central Universities of Central South University (2023ZZTS0924)
- Natural Science Foundation of Hunan Province (2023JJ60503)
This publication has 31 references indexed in Scilit:
- Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the USJAMA Network Open, 2024
- Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial CarcinomaNew England Journal of Medicine, 2023
- Avelumab Maintenance Treatment After First-line Chemotherapy in Advanced Urothelial Carcinoma–A Cost-Effectiveness AnalysisClinical Genitourinary Cancer, 2022
- Cost-Effectiveness Analysis of Pertuzumab Plus Trastuzumab and Docetaxel Compared With Trastuzumab and Docetaxel in the Adjuvant Treatment of Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer in ColombiaValue in Health Regional Issues, 2022
- Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese SettingPharmacoEconomics, 2022
- Cost Effectiveness of Nivolumab in Advanced Renal Cell CarcinomaEuropean Urology, 2018
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness AnalysesJAMA, 2016
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY ThresholdNew England Journal of Medicine, 2014
- Development of WHO guidelines on generalized cost-effectiveness analysisHealth Economics, 2000
- Factors influencing the prognosis in bladder cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1986